AstraZeneca (NYSE:AZN) CEO David Brennan deflected reports that some shareholders are looking for a change in management in the firm.The CEO has received heavy criticism for his plans to pursue smaller deals and avoid large mergers in the face of potentially declining sales on major drugs with patent protection due to expire.
